![]() Abstract Reports Curtana's CT-179 Extends Survival as a Single Agent in a Patient-Derived Model of Diffuse Midline GliomaPreclinical study of the first-in-class, brain-penetrant OLIG2 inhibitor will be presented at the 31st Annual Meeting of the Society for Neuro-Oncology
AUSTIN, Texas - Nov. 3, 2026 - PRLog -- Curtana Pharmaceuticals, a clinical-stage biotechnology company focused on improving outcomes for brain cancer patients, today announced that an abstract published in the online program of the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), to be held November 12 to 15 in Philadelphia, reports that CT-179 significantly extended survival as a single agent in an orthotopic patient-derived xenograft model of H3 K27M-mutant diffuse midline glioma (DMG). CT-179 is a first-in-class, orally bioavailable, brain-penetrant small-molecule inhibitor of the transcription factor OLIG2.
DMG, which includes diffuse intrinsic pontine glioma (DIPG), is a lethal pediatric brain tumor with median overall survival under one year, and radiation remains the only standard of care. ONC201 (dordaviprone) Key findings reported in the abstract:
"Diffuse midline glioma is a priority indication for Curtana, and a significant single-agent survival benefit in an orthotopic H3 K27M model is an important step for the program," said Gregory Stein, M.D., M.B.A., Chief Executive Officer of Curtana Pharmaceuticals. "Single-agent activity is the foundation for any combination strategy in this disease. The tissue analyses now under way will tell us whether CT-179 is engaging OLIG2 in these tumors and will guide dose selection as we evaluate rational combinations, including radiation, the standard of care in DMG." About the Abstract Mizoguchi SF, Yu J, Yadavilli S, Stein G, Kesari S, Packer R, Nazarian J. In vitro and in vivo evaluation of CT-179 in combination with ONC201 and ONC206 in patient-derived models of diffuse midline glioma. Published in the online program of the 31st Annual Meeting of the Society for Neuro-Oncology, Philadelphia, PA, November 12 to 15, 2026. SNO Annual Meeting abstracts are published in a supplement to Neuro-Oncology. About CT-179 CT-179 is a first-in-class, orally bioavailable, brain-penetrant small-molecule inhibitor of OLIG2, a master transcription factor in diffuse gliomas and OLIG2-positive medulloblastoma. CT-179 is designed to eliminate the cancer stem cells that drive recurrence, and published preclinical work shows that OLIG2 inhibition also relieves tumor-driven suppression of CXCL10 and sensitizes GBM to anti-PD-L1 therapy. The FDA has granted CT-179 Fast Track Designation, Orphan Drug Designation for gliomas, and Rare Pediatric Disease Designation for medulloblastoma and for pediatric high-grade glioma. Curtana's multi-site Phase 1 OPAL trial of CT-179 in glioblastoma will be conducted in Australia in partnership with the Cooperative Trials Group for Neuro-Oncology (COGNO). About Curtana Pharmaceuticals Curtana Pharmaceuticals, founded in 2013, is a privately held, clinical-stage biopharmaceutical company headquartered in Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, the Musella Foundation, the Hasso Serrano Foundation, the Uncle Kory Foundation, and other anonymous investors. The company was also awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Curtana focuses on the development of novel, first-in-class small-molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma, low-grade glioma, medulloblastoma, diffuse midline glioma, and other brain cancers. For more information, visit https://www.curtanapharma.com/ Forward-Looking Statements This press release contains forward-looking statements regarding the preclinical and clinical development of CT-179, including its potential in diffuse midline glioma and in combination with radiotherapy and other agents, and the design and conduct of the multi-site Phase 1 OPAL study in glioblastoma. Results in preclinical models may not be predictive of results in patients, and data presented in abstract form are preliminary and subject to change. These forward-looking statements involve risks and uncertainties, including the complexities of clinical trial execution and patient accrual and the need to secure additional capital to fund operations and clinical milestones. Curtana undertakes no obligation to update these statements. End
|